# Taysha Gene Therapies, Inc. (TSHA): MoatMap facts

As of 27 Oct 2026. Research data, not investment advice.

As of 27 Oct 2026, MoatMap's StockRank for Taysha Gene Therapies, Inc. (TSHA) is 8/100, ranked against 24,000+ stocks in 35 markets (Quality 26, Value 25, Momentum 27, each scored against its sector).

- StockRank: 8/100, a percentile across 24,000+ stocks in 35 markets (100 is best).
- Quality 26, Value 25, Momentum 27: each a 0-100 percentile within Healthcare.
- Position: #24,459 overall, #2,387 in Healthcare.
- Listing: United States, NMS; Healthcare / Biotechnology.
- Last close: 4.01 USD on 26 Oct 2026.
- Insider filings, last 180 days: directors sold USD 1.2M.

Source: https://moatmap.ai/stock/TSHA
How the scores work: https://moatmap.ai/methodology
Does StockRank work? The public record: https://moatmap.ai/decile-tracker